E&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015

Transcription

1 E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015

2 Education adapted to demand? Declining number of students choosing science Education still based on current and not future needs

3 Education and Training in IMI1 Gaps identified in 2008 Research Agenda Silos organisation in acadamic education Bi-directional movements of scientists to exchange knowledge Little or no interaction between scientists across R&D chain New skills in safety, pharmacology, bioinformatics, biosimulation, knowledge management,...

4 Predictions of economists and scientists converge: 70% of the jobs that will exist in 20 years don't exist today We will have 5 careers and at least 15 jobs As our economy changes, we ve got to move with it

5 Evolution: the world around us More demanding, less complacent Society People Information technology Economy Scrutiny Europe All with impact on healthcare ecosystem

6 Evolution: science and technology Science more exciting and promising than ever More diverse R&D toolbox Life science integrates more disciplines every day

7 7

8 A revolutionary period in R&D Wealth of Data High-speed, low-cost genomic sequencing Increased availability of human tissue samples Increased access to clinical trial data, and electronic medical records New Technologies Stem cells, cell and gene therapy, RNAi Advance in medical devices, imaging, robotics M-Health Increased input of health stakeholders Doctors, Patients, Regulators

9 Medicines Adaptive Pathways to Patients (MAPPs): New research, development and access paradigms

10 Evolution: the industry (-ies?) From vertical integration to externalisation and open collaboration From market access to patient access and outcomes From products to therapies From pharma only/mainly to ecosystems where we do not always hold the keys of success

11 H E A L T H & G R O W T H 11

12 IMI Europe s partnership for health > 5 bn 2.5 bn Partnership bn

13 IMI2 vision: towards integrated healthcare solutions Addressing healthcare priorities identified by the WHO 2013 report Strategic Research Agenda aimed at progressing the vision of stratified medicines: prevention, treatment and health management Entire product cycle from discovery, through development to healthcare delivery and access models Collaboration across sectors to harness all knowledge and technologies which can contribute to IMI2 vision - diagnostics, imaging, IT, medical devices,

14 IMI2 Strategic Research Agenda: reduced attrition, faster patient access, improved outcomes

15 First five big themes Therapeutic Areas and Cross-cutting Themes Differentiating Enablers for all themes Neuro-degeneration Successfully prevent and treat dementia and other neurodegenerative diseases Prevention and treatment of immunemediated disease Advance immunological understanding to deliver new medicines and new and better vaccines Metabolic disorders Tackle all phases of disease and its complications, including prevention and early interception Infection control Address big societal problem related to multidrug resistance and develop new and better vaccines Translational Safety Development of new human biology platform to predict toxicity and safety during early drug development Towards early and effective patient access to innovative prevention and treatment solutions (MAPPs): Target validation based on human biology Stratified medicine, precision medicine Innovation in clinical trials Data generation and interpretation (knowledge management) Prevention, disease interception, patient adherence (incl. societal acceptance of vaccines) Effect on medical practice and outcomes (health/disease management) Regulatory framework (including pharmacovigilance) Patient access

16 Education and Training in IMI2

17 Implementation: various models are possible, e.g. Project 1 Project 2 Project 3 Project 50 E&T E&T E&T E&T Education and Training Infrastructures - dedicated platform(s), CPD, university cursus...